This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 25/3/560    most recent 01.ATV.0000155323.18856.a2v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Millar, J. S. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Millar, J. S. Articles by Rader, D. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Cholesterol Genetics Home Reference Hazardous Substances DB TRITIUM Related Collections Genetics of cardiovascular disease Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:560.)
© 2005 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production

John S. Millar; Cyrille Maugeais; Katsunori Ikewaki; Daniel M. Kolansky; P.Hugh R. Barrett; Elaine C. Budreck; Raymond C. Boston; Norio Tada; Seibu Mochizuki; Joep C. Defesche; James M. Wilson; Daniel J. Rader

From the Department of Medicine (J.S.M., C.M., D.M.K., E.C.B., J.M.W., D.J.R.), University of Pennsylvania, Philadelphia; the Division of Cardiology (K.I., S.M.), Department of Internal Medicine and the Department of General Medicine (N.T.), Kashiwa Hospital, Jikei University School of Medicine, Tokyo, Japan; the School of Medicine and Pharmacology (P.H.R.B.), University of Western Australia, Perth; the Biomathematics Unit (R.C.B.), University of Pennsylvania School of Veterinary Medicine, Kennett Square; and the Department of Vascular Medicine (J.C.D.), Academic Medical Center at the University of Amsterdam, the Netherlands.

Correspondence to John S. Millar, PhD, University of Pennsylvania, 644 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail jsmillar{at}mail.med.upenn.edu

Objective— We addressed the role of the low-density lipoprotein (LDL) receptor in determining clearance rates and production rate (PR) of apolipoprotein B (apoB) in humans.

Methods and Results— Kinetic studies using endogenous labeling of apoB with deuterated leucine were performed in 7 genetically defined patients with homozygous familial hypercholesterolemia (FH) and compared with 4 controls. The fractional catabolic rates (FCR) and PRs for apoB were determined by multicompartmental modeling. The FCRs of very-low-density lipoprotein 1 (VLDL1), VLDL2, intermediate-density lipoprotein (IDL), and LDL apoB were lower in FH than in controls, with the LDL apoB FCR being significantly lower (0.148±0.049 versus 0.499±0.099 pools · d^–1; P=0.008). Whereas receptor-defective FH patients had a total apoB PR similar to controls, receptor-null FH patients had a significantly greater total apoB PR than controls (35.97±10.51 versus 21.32±4.21 mg · kg^–1 · d^–1, respectively; P=0.02).

Conclusions— This first study of apoB metabolism in homozygous FH using endogenous labeling with stable isotopes demonstrates that the LDL receptor contributes significantly to the clearance of LDL from plasma but plays a lesser role in the clearance of larger apoB-containing lipoproteins. Furthermore, these data also indicate that absence of a LDL receptor in humans substantially influences the apoB PR in vivo.

Kinetic studies on apoB were conducted in genetically defined patients with homozygous FH. FH patients had significantly decreased clearance of LDL apoB. Receptor-null FH had a significantly increased apoB production. We conclude that the LDL receptor primarily mediates clearance of LDL apoB from plasma and can influence apoB production in vivo.

Key Words: cholesterol • familial hypercholesterolemia • VLDL • LDL • apoB

This article has been cited by other articles:

				D. A. Blasiole, A. T. Oler, and A. D. Attie Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB J. Biol. Chem., April 25, 2008; 283(17): 11374 - 11381. [Abstract] [Full Text] [PDF]

				M. Pan, V. Maitin, S. Parathath, U. Andreo, S. X. Lin, C. St. Germain, Z. Yao, F. R. Maxfield, K. J. Williams, and E. A. Fisher Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: A pathway for late-stage quality control PNAS, April 15, 2008; 105(15): 5862 - 5867. [Abstract] [Full Text] [PDF]

				M. Cuchel, L. T. Bloedon, P. O. Szapary, D. M. Kolansky, M. L. Wolfe, A. Sarkis, J. S. Millar, K. Ikewaki, E. S. Siegelman, R. E. Gregg, et al. Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia N. Engl. J. Med., January 11, 2007; 356(2): 148 - 156. [Abstract] [Full Text] [PDF]

				G. Lambert, A.-L. Jarnoux, T. Pineau, O. Pape, M. Chetiveaux, C. Laboisse, M. Krempf, and P. Costet Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor Endocrinology, October 1, 2006; 147(10): 4985 - 4995. [Abstract] [Full Text] [PDF]

				C. Zheng, K. Ikewaki, B. W. Walsh, and F. M. Sacks Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat J. Lipid Res., August 1, 2006; 47(8): 1771 - 1779. [Abstract] [Full Text] [PDF]

				K. G. Parhofer and P. H. R. Barrett Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies J. Lipid Res., August 1, 2006; 47(8): 1620 - 1630. [Abstract] [Full Text] [PDF]

				J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. Hugh, R. Barrett, F. K. Welty, A. Faruqi, M. L. Wolfe, C. Nartsupha, A. G. Digenio, et al. Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1350 - 1356. [Abstract] [Full Text] [PDF]